12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.
Glycostem collaborates with LUMICKS
30th July, 2020 - LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development.
Glycostem enters contract with Autolomous to digitise manufacturing process
3rd June, 2020 – Autolomous Ltd, a leading edge developer of innovative digital solutions for manufacture of advanced medicines, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company, today a
Glycostem partners with Zelluna Immunotherapy
19th November, 2019 - Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company, today announce that they have entered into a de
Glycostem welcomes Dr Rizwan Romee as US based advisor
12th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK cell company,today announced to have welcomed Rizwan
Glycostem signs first commercial agreement for oNKord® and new CAR-NK co-development agreement
11th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced the signing of a two agreements wit
Glycostem successfully completes funding round
9th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company today announced that inno.N, E&F Healthcare Holdings and existing investor LUPUS Ventures B.V.(LUPUS)
Glycostem raises €5 million for clinical trials
September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced they have been awarded a €5 million loan from RVO’s Innovation Credit budget for clinical trials
Glycostem received GMP license for oNKord®
25th June 2019 - Glycostem Therapeutics BV today announced they have received GMP license for Glycostem’s proprietary closed production system used to manufacture their lead product, oNKord®, an off-the-shelf,allogeneic Natural Killer(NK) cell therapy.